Loading…
COYA
Coya Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 22407B108
$4.59-5.56%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $107.67M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.01
- ROE
- -60.54%
- Profit margin
- -270.22%
- Revenue growth
- +49.00%
- Beta
- —
- 52-week high
- $7.75
- 52-week low
- $3.71
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +7.2% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.80 | $5.73 | $7.41 | $4.74 | |
| P/S | 18.0x | 17.1x | 27.0x | 18.0x | — |
| P/B | 3.0x | 3.2x | 2.4x | 3.0x | — |
| EPS | -$1.27 | -$0.98 | -$0.79 | -$4.73 | |
| Profit margin | -267.14% | -267.14% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ONCYOncolytics Biotech Inc | $0.86 | — | — | — | — | $109.23M |
| CCLDCareCloud, Inc. | $2.49 | 35.6x | 6.1x | — | 21.75% | $105.81M |
| CRDFCardiff Oncology, Inc. | $1.33 | — | 3.4x | — | -94.08% | $103.47M |
| PYPDPolyPid Ltd. | $5.07 |
About the company
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
- 8
- Houston, United States
Company description provided by Yahoo Finance.